Novel Ciprofloxacin-Resistant, Nalidixic Acid-Susceptible Mutant of Staphylococcus aureus
- 1 July 2002
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 46 (7) , 2276-8
- https://doi.org/10.1128/aac.46.7.2276-2278.2002
Abstract
A ciprofloxacin-resistant, nalidixic acid-susceptible mutant of Staphylococcus aureus (F145) contained no mutations within gyrA, gyrB, grlA, and grlB or within norA or its promoter region. MICs and accumulation studies suggest the role of a novel multidrug efflux pump.Keywords
This publication has 14 references indexed in Scilit:
- Accumulation of 10 Fluoroquinolones by Wild-Type or Efflux Mutant Streptococcus pneumoniaeAntimicrobial Agents and Chemotherapy, 2002
- Whole genome sequencing of meticillin-resistant Staphylococcus aureusThe Lancet, 2001
- Evidence for the Existence of a Multidrug Efflux Transporter Distinct from NorA in Staphylococcus aureusAntimicrobial Agents and Chemotherapy, 2000
- Efflux Pump-Mediated Quinolone Resistance in Staphylococcus aureus Strains Wild Type for gyrA , gyrB , grlA , and norAAntimicrobial Agents and Chemotherapy, 1999
- Inducible NorA-mediated multidrug resistance in Staphylococcus aureusAntimicrobial Agents and Chemotherapy, 1995
- Cloning and primary structure of Staphylococcus aureus DNA topoisomerase IV: a primary target of fluoroquinolonesMolecular Microbiology, 1994
- Mechanism of action of sparfloxacin against and mechanism of resistance in gram-negative and gram-positive bacteriaAntimicrobial Agents and Chemotherapy, 1991
- A comparison of methods used for measuring the accumulation of quinolones by Enterobacteriaceae, Pseudomonas aeruginosa and Staphylococcus aureusJournal of Antimicrobial Chemotherapy, 1991
- Ciprofloxacin resistance in coagulase-positive and -negative staphylococci: role of mutations at serine 84 in the DNA gyrase A protein of Staphylococcus aureus and Staphylococcus epidermidisAntimicrobial Agents and Chemotherapy, 1991
- Mechanisms of quinolone resistance in a clinical isolate of Escherichia coli highly resistant to fluoroquinolones but susceptible to nalidixic acidAntimicrobial Agents and Chemotherapy, 1991